Stock NEUN NEUROGENESIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurogenesis, Inc.

Equities

NEUN

US64124F3010

Market Closed - OTC Markets
Other stock markets
 19:49:23 12/06/2024 BST 		5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for Neurogenesis, Inc. 0.00% 0.00%
2023 Neurogenesis, Inc. Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome CI
2021 Neurogene Inc. and University of Edinburgh Announces Research Collaboration to Advance Next Generation Gene Therapies CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurogenesis, Inc. Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
CI
Neurogene Inc. and University of Edinburgh Announces Research Collaboration to Advance Next Generation Gene Therapies
CI
Hadassah Medical Center and Neurogenesis Announce Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01 Autologous Cells Therapy
CI
Neurogene Names Kenneth Huttner as Senior VP of Clinical Development
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NEUN Stock
  4. News Neurogenesis, Inc.